CLINICAL TRIALS PROFILE FOR ALFUZOSIN HYDROCHLORIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for alfuzosin hydrochloride
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT00280605 ↗ | ALF-ONE : ALFuzosin ONcE Daily | Completed | Sanofi | Phase 4 | 2005-08-01 | The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). |
| New Formulation | NCT00542165 ↗ | Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy | Completed | Sanofi | Phase 4 | 2004-03-01 | To collect under daily practice conditions, clinical data on the changes of sexual function when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with lower urinary tract symptoms(LUTS) suggestive of prostatic hypertrophy |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for alfuzosin hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00029822 ↗ | Clinical Trial in Males With BPH (Enlarged Prostate) | Completed | Sanofi | Phase 3 | 2001-05-01 | A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH. - Free study-related medical care provided. |
| NCT00064649 ↗ | Minimally Invasive Surgical Therapy for BPH | Terminated | Diagnostic Ultrasound | Phase 3 | 2004-04-01 | The primary objective of this randomized clinical trial is to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. |
| NCT00064649 ↗ | Minimally Invasive Surgical Therapy for BPH | Terminated | Medtronic | Phase 3 | 2004-04-01 | The primary objective of this randomized clinical trial is to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. |
| NCT00064649 ↗ | Minimally Invasive Surgical Therapy for BPH | Terminated | Merck Sharp & Dohme Corp. | Phase 3 | 2004-04-01 | The primary objective of this randomized clinical trial is to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. |
| NCT00064649 ↗ | Minimally Invasive Surgical Therapy for BPH | Terminated | Sanofi-Synthelabo | Phase 3 | 2004-04-01 | The primary objective of this randomized clinical trial is to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. |
| NCT00064649 ↗ | Minimally Invasive Surgical Therapy for BPH | Terminated | Urologix | Phase 3 | 2004-04-01 | The primary objective of this randomized clinical trial is to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for alfuzosin hydrochloride
Condition Name
Clinical Trial Locations for alfuzosin hydrochloride
Trials by Country
Clinical Trial Progress for alfuzosin hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for alfuzosin hydrochloride
Sponsor Name
